Future investigations exploring the role of clinically relevant genetic aberrations in RNF43 and ZNRF3 during primary and metastatic prostate cancer will be important to ascertain their impact on Wnt signaling. The gene discussed is ZNRF3; the disease is metastatic prostate carcinoma.